Paper Details

  1. Home
  2. Paper Details

[EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].

Author: ChenL L, ChengX D, LyuW G, QinJ L, ShenT, WangX Y, XieX

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the effectiveness and toxicity of the EMA/CO regimen for treating ultra-high-risk gestational trophoblastic neoplasia (GTN). The regimen achieved complete remission in 67% of patients, with manageable side effects.
Paper Details　
Original Abstract of the Article :
<b>Objective:</b> To evaluate etoposide, methotrexate and dactinomycin (EMA) /cyclophosphamide and vincristine (CO) regimen for treatment of ultra high-risk gestational trophoblastic neoplasia (GTN) . <b>Methods:</b> A total of twenty-four ultra high-risk patients who had International Federation o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3760/cma.j.issn.0529-567x.2018.06.003

データ提供：米国国立医学図書館（NLM）

EMA/CO Regimen for Ultra High-Risk Gestational Trophoblastic Neoplasia

Gestational trophoblastic neoplasia (GTN), a rare but potentially life-threatening condition, requires aggressive treatment. This study evaluates the efficacy and safety of the etoposide, methotrexate, and dactinomycin (EMA)/cyclophosphamide and vincristine (CO) regimen for treating ultra high-risk GTN patients. The researchers retrospectively analyzed clinical data from 24 patients with FIGO prognostic scores greater than or equal to 12, examining the treatment response and toxicity of the EMA/CO regimen.

Effective Treatment Strategies for Ultra High-Risk GTN

The study demonstrates that the EMA/CO regimen is an effective treatment option for patients with ultra high-risk GTN, achieving a complete remission rate of 67%. These findings highlight the importance of individualized treatment strategies tailored to the specific needs of patients with high-risk GTN.

Navigating the Complexities of Gestational Trophoblastic Neoplasia

Just as a camel navigates the vast and unpredictable desert, treating GTN requires a careful and strategic approach. This study provides valuable insights into the efficacy and safety of the EMA/CO regimen for managing ultra high-risk GTN, highlighting the importance of individualized treatment plans and careful monitoring of patient outcomes.

Dr. Camel's Conclusion

This study examines the effectiveness of the EMA/CO regimen for treating ultra high-risk gestational trophoblastic neoplasia (GTN). The research highlights the efficacy of this regimen in achieving complete remission, demonstrating its potential as a valuable treatment option for patients with high-risk GTN. This study emphasizes the importance of individualized treatment strategies tailored to the specific needs of these patients.

Date :
  1. Date Completed 2018-07-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

29961278

DOI: Digital Object Identifier

10.3760/cma.j.issn.0529-567x.2018.06.003

Related Literature

Article Analysis
・Side Effects of dactinomycin
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.